A Randomized Phase II, Double-Blind, Multicenter Study Evaluating The Efficacy And Safety Of Autogene Cevumeran Plus Nivolumab Versus Nivolumab As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma
Evaluating the Efficacy & Safety of Autogene Cevumeran + Nivolumab VS Nivolumab Alone for High-Risk Muscle-Invasive Urothelial Carcinoma
Sponsor: Roche
Enrolling: Male and Female Patients
IRB Number: AAAV2596
U.S. Govt. ID: NCT06534983
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is testing a drug called autogene cevumeran in combination with nivolumab, a cancertreatment drug known for treating bladder cancer. The purpose of this study is to compare the effects, good or bad, of autogene cevumeran plus nivolumab versus nivolumab on patients with Muscle Invasive Urothelial Carcinoma (MIUC.) In this study, you will get either autogene cevumeran plus nivolumab or saline plus nivolumab. Autogene Cevumeran is not approved by the Food and Drug Administration to treat muscle-invasive urothelial cancer.
Investigator
Alexander Wei, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with muscle-invasive urothelial carcinoma of the bladder or upper urinary tract? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE